These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34921439)

  • 1. Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A.
    Bukkems LH; Valke LLFG; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Cnossen MH; van Heerde WL; Schols SEM; Mathôt RAA
    Br J Clin Pharmacol; 2022 Jun; 88(6):2757-2768. PubMed ID: 34921439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate.
    Valke LLFG; Cloesmeijer ME; Mansouritorghabeh H; Barteling W; Blijlevens NMA; Cnossen MH; Mathôt RAA; Schols SEM; van Heerde WL
    Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):191-205. PubMed ID: 38367175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.
    Valke LLFG; Bukkems LH; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Mathôt RAA; van Heerde WL; Schols SEM
    J Thromb Haemost; 2020 Dec; 18(12):3222-3231. PubMed ID: 32979031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
    Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
    Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.
    Fernández-Bello I; Rode F; Álvarez-Román MT; Butta NV; Rivas-Muñoz S; Hernández-Moreno AL; de la Corte-Rodríguez H; Martín-Salces M; Larsen LF; Jiménez-Yuste V
    Eur J Pharm Sci; 2019 Feb; 128():215-221. PubMed ID: 30529268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients.
    Romano LGR; Schütte LM; van Hest RM; Meijer K; Laros-van Gorkom BAP; Nieuwenhuizen L; Eikenboom J; Heubel-Moenen FCJI; Uitslager N; Coppens M; Fijnvandraat K; Driessens MHE; Polinder S; Cnossen MH; Leebeek FWG; Mathôt RAA; Kruip MJHA;
    Haemophilia; 2024 Mar; 30(2):355-366. PubMed ID: 38343113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new paradigm for personalized prophylaxis for patients with severe haemophilia A.
    Delavenne X; Ollier E; Lienhart A; Dargaud Y
    Haemophilia; 2020 Mar; 26(2):228-235. PubMed ID: 32100950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
    Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?
    Goedhart TMHJ; Bukkems LH; van Moort I; Spence CC; Zwaan MC; de Maat MPM; Mathôt RAA; Cnossen MH;
    Haemophilia; 2022 Jul; 28(4):610-618. PubMed ID: 35526235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.
    Tegenge MA; Yang H; Forshee RA
    Haemophilia; 2017 Sep; 23(5):705-711. PubMed ID: 28543946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
    Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
    Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model.
    Zhu J; Wu YS; Beechinor RJ; Kemper R; Bukkems LH; Mathôt RAA; Cnossen MH; Gonzalez D; Chen SL; Key NS; Crona DJ
    Haemophilia; 2021 Nov; 27(6):974-983. PubMed ID: 34405493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.
    Lewis SJ; Stephens E; Florou G; Macartney NJ; Hathaway LS; Knipping J; Collins PW
    Br J Haematol; 2007 Sep; 138(6):775-82. PubMed ID: 17672884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.
    Huang K; Zhen Y; Li G; Wu X; Chen Z; Wu R
    Haemophilia; 2021 Jul; 27(4):e450-e457. PubMed ID: 34015176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profile of children with haemophilia A receiving low-dose FVIII prophylaxis in Indonesia: A single centre experience.
    Primacakti F; Sari TT; Gatot D; Sjakti HA; Chozie NA
    Haemophilia; 2022 Sep; 28(5):720-725. PubMed ID: 35537097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
    Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.